**Relationship between diabetes mellitus and clinicopathological stages of breast cancer at diagnosis**

*Ali Hasaneen#, Mohamed Ahmed#, Nabil Khattab#, Abdel-Shafi Table#, and Reham Emam Ali#*

*#Internal Medicine Department, Faculty of Medicine, Benha University, Egypt*

**Abstract**

Diabetes is a risk factor for development of specific neoplasms, including breast cancer. Women with type-2 diabetes mellitus (T2DM) are at increased risk for developing breast cancer. Breast cancer subtypes have been extensively studied, but few studies have examined whether diabetic women present with more advanced breast cancer stages. **Aim of study**: evaluate whether T2DM has effect on clinicopathological stages of breast cancer at diagnosis. **Subjects and methods**: 102 breast cancer women were studied, 51 had T2DM and 51 were non-diabetic. Clinical assessment, BMI, FBS, 2-hPPBS, HbA1c level, total cholesterol, triglyceride, C-peptide, breast mammography, and body imaging and scanning were performed. Biopsy samples from breast tissues were reviewed; histologic morphology and grades were determined. Hormone receptor status (ER, PR, HER2) was determined. Clinical stages of breast cancer were determined based on TNM staging system. **Results**: BMI was significantly higher in type-2 diabetic breast cancer women compared to non-diabetic. Type-2 diabetic breast cancer women had more invasive pathologic subtypes and advanced stages of breast cancer compared to those who were non-diabetic. Breast cancer women with invasive duct carcinoma had significantly higher BMI (32.0±6.1kg/m2), FBS (130.3±30.4mg/dL), 2-hPPBS (221.6±72.5mg/dL), HbA1c (7.8±2.2%), cholesterol (202.2±39.9mg/dL), and triglyceride (154.9±16.1mg/dL) compared to those with ductal carcinoma in situ. **Conclusion and recommendation**: breast cancer in type-2 diabetic women is often diagnosed at advanced stages and being of more aggressive pathologic subtype. Whether proper control of diabetic status has effect on progression of breast cancer needs further studies.

**Key words**: breast cancer, clinicopathological stages, diabetes mellitus.

**Introduction**:

Diabetes is emerging as one of the most prevalent human aliments next to cardiovascular diseases and is the sixth leading cause of death worldwide [1]. A number of studies have related diabetes to cancer risk; furthermore, growing evidences suggested an abnormal glucose homeostasis as an independent risk factor for the development of specific neoplasms [2]. Diabetes mellitus and breast cancer are chronic diseases with increasing incidence in many countries [3]. Women with type-2 diabetes mellitus (T2DM) are at increased risk of developing breast cancer, which is the most common malignant tumor in females [4]. Women with diabetes have a 15-20% increased risk of breast cancer compared to women without diabetes, and breast cancer in women with diabetes is often diagnosed at an advanced stage compared to women without diabetes [5].

Several mechanisms have been suggested for the increased risk of breast cancer among women with T2DM, such as the common risk factors (like obesity), the specific metabolic derangements of diabetes itself (i.e., hyperglycemia, hyperinsulinemia, and insulin resistance) and the sue of insulin and specifically insulin analogs [6]. Hyperinsulinemia in itself, especially present in people with impaired glucose tolerance, may promote tumor cell growth directly via insulin receptors or indirectly via insulin-like growth factor-1 (IGF-1) receptors [7]. IGF-1, and subsequently the IGF-1 receptor, could act as a growth stimulus for tumor cells and increase tumor growth, invasion, and metastases [8].

Women with diabetes have a 40% higher risk of death after breast cancer compared to women without diabetes; the comorbidity and diabetes-related complications may contribute to high all-cause mortality; however, diabetes also increases the risk of breast-cancer-specific deaths [9]. Another reason for the worse breast cancer survival may be that women with diabetes develop a more aggressive or less treatment-responsive tumor subtype. It has been shown that hormone-related breast cancer and diabetes risk factors, such as obesity, are associated with development of estrogen receptor (ER)-negative breast cancer subtypes [3]. Insulin interacts with estrogens; there is experimental support that insulin may enhance estrogen production, stimulating the development of ER-positive breast cancer [10].

Breast cancer subtypes have been extensively studied in the general population [3]. Yet, few studies have examined whether women with diabetes present with more advanced breast cancer stage [9].

**Aim of study**

The aim of this study is to evaluate whether type-2 diabetes mellitus has an effect on the clinicopathological stage of breast cancer at diagnosis.

**Subjects and methods**

This study was conducted at Hematology-Oncology Unit, Internal Medicine Department, Benha University Hospital, Egypt, during the period from January 2019 to February 2020 and included 102 patients diagnosed with breast cancer. This study was approved by ethics committee of Benha University Hospital. The patients were informed about the nature of study and written consents were obtained from them. Adult women, aged 30 years or older, with histopathologic-confirmed unilateral breast cancer, having type-2 diabetic or non-diabetics, and having different body weights were included in present study. Exclusion criteria include younger patients, women with type-1 diabetes mellitus, women with bilateral breast cancers, women with other malignancy, and male patients with breast cancer. The diagnosis of breast cancer and its pathologic subtypes were determined based on the results of breast tissue biopsy samples [11], and the diagnosis of T2DM was made according to American Diabetic Association (ADA), 2014 (based on the patient's age, body weight overweight/obesity, fasting blood sugar "FBS" of 126mg/dL or more, 2-hour post-prandial blood sugar "2-hPPBS" of 200mg/dL or more, random blood sugar "RBS" of 200mg/dL or more, glycosylated hemoglobin "HbA1c" of 6.5% or more, normal or elevated serum insulin and C-peptide levels, and absence of specific antibodies against islet β-cells) [12]. The patients were categorized into two groups: group-A (women with T2DM and breast cancer, and included 51 women) and group-B (women with breast cancer who were non-diabetic, and included 51 women, and used as a comparison group). All included patients were subjected to full history taking and thorough physical examination. Patient's height, body weight, and body mass index (BMI) were determined. From each patient, venous blood sample (5mL) was obtained from antecubital vein under aseptic technique, centrifuged, and stored for later determination of various serum parameters, which included FBS level, 2-hPPBS level, RBS level, HbA1c level, serum lipids profile (total cholesterol, low-density lipoprotein "LDL" cholesterol, high-density lipoprotein "HDL" cholesterol, and triglyceride levels), C-peptide, and anti-islets antibodies. Breast mammography was done to confirm the presence of breast mass and to exclude presence of contralateral breast mass. Body imaging and scanning were performed to determine lymph node affects and distant metastases. The breast's biopsy samples were reviewed by expert pathologist to confirm the diagnosis of breast cancer, determine morphology (ductal, lobular, mixed), histologic grades (grade-I "well-differentiated", grade-II "moderately-differentiated, and grade-III "poorly-differentiated"); in addition, hormone receptor status, including estrogen receptor (ER), progesterone receptor (PR), and hormone epidermal growth factor receptor "herpceptin-2" (HER2) was determined [11]. The clinical stages of breast cancer, determined according to the American Joint Committee of Cancer (AJCC) 2017 and based on TNM staging system (T is tumor size; N is lymph nodes status; M is distant metastasis), were categorized into stage-0, stage-I (Ia, Ib), stage-II (IIa, IIb), stage-III (IIIa, IIIb, IIIc), and stage-IV [13].

**Statistical methods**

Statistical analyses were done using SPSS (Statistical Package of Social Science), version 20 (SPSS Statistics for Windows, version 20; Armonk, New York: IBM Corp., Released 2011). Kolmogorov Smirnov test was done to test the normality of data distribution. Numerical data were expressed as number, mean, and standard deviation (SD); non-numerical data were expressed as frequency and percentage. Student t-test was used to assess the statistical significance of the difference between means of study groups. Chi-Square test was used to examine the relationship between two qualitative data. Fisher's exact test was used to examine the relationship between two qualitative variables when the expected count is less than 5 in more than 20% of cells. All reported p values were two-tailed, and p value less than 0.05 (P < 0.05) was considered to be significant [14].

**Results**

This study was conducted during the period from January 2019 to February 2020 and included 102 breast cancer women, 51 women (50%) had breast cancer and type-2 diabetes and 51 women (50%) had breast cancer but were non-diabetic. The mean age ± SD of type-2 diabetic breast cancer patients was 47.2±9.2 years and that of non-diabetic breast cancer patients was 45.5±11.1 years with non-significant difference regarding age between type-2 diabetic and non-diabetic breast cancer patients (p value = 0.39) (table 1). Also, table 1 showed that in type-2 diabetic breast cancer women, mean level ± SD of BMI was 34.7±4.5 kg/m2, of cholesterol was 214.2±39.8mg/dL, of triglyceride was 159.5±15.8mg/dL, of FBS was 145.4±18.1mg/dL, of 2-hPPBS was 254.5±54.1mg/dL, and of HbA1c was 9.1±1.4%, which were significantly higher compared to their levels in non-diabetic breast cancer women, with P values of 0.01, 0.001, 0.01, 0.001, 0.001, and 0.001, respectively (table 1).

Table 2 showed that HER2 receptor was positive in 11.8% of patients with type-2 diabetic breast cancer and in 9.8% of non-diabetic breast cancer patients, with no significant difference between the two groups (P value = 0.974). The ER receptor was positive in 84.3% of type-2 diabetic breast cancer patients and in 51% of non-diabetic breast cancer patients; the prevalence of ER-positivity was significantly higher in breast cancer patients with type-2 diabetes compared to non-diabetic breast cancer patients (P value = 0.001). The PR receptor was positive in 64.7% of type-2 diabetic breast cancer patients and in 56.9% of non-diabetic breast cancer patients, with no significant difference among the two groups regarding PR-positivity (p value = 0.417). In non-diabetic breast cancer women, ductal carcinoma in situ was found in 64.7% of cases and invasive ductal carcinoma was found in 35.3% of women; on the other hand, 3.9% of women with type-2 diabetes and breast cancer had ductal carcinoma in situ and 96.1% had invasive ductal carcinoma. Significant differences regarding prevalence of pathologic types of breast cancer were reported between type-2 diabetic breast cancer women and non-diabetic breast cancer women (p value = 0.001). Regarding clinical staging of breast cancer, 58.8% of non-diabetic breast cancer women had stage-I disease, 31.4% had stage-II disease, and 9.8% had stage-III disease; on the other hand, 41.2% of type-2 diabetic breast cancer women had stage-II disease, 58.8% had stage-III disease, but none had stage-I disease. Significant differences regarding clinical stages were observed between type-2 diabetic breast cancer women compared to non-diabetic breast cancer women (p value = 0.001) (table 2).

As shown in table 3, breast cancer women with stage-I disease had BMI of 22.8±1.4 kg/m2, FBS level of 84.8±7.4mg/dL, 2-hPPBS level of 128.3±5.7mg/dL, HbA1c level of 4.8±0.5%, cholesterol level of 165.9±5.4mg/dL, and triglyceride level of 140.0±6.2mg/dL. Breast cancer women with stage-II disease had BMI of 28.2±4.3 kg/m2, FBS level of 123.1±35.0mg/dL, 2-hPPBS level of 202.7±68.6mg/dL, HbA1c level of 6.9±2.2%, cholesterol level of 194.2±40.2mg/dL, and triglyceride level of 152.5±15.6mg/dL. Breast cancer women with stage-III disease had BMI of 35.3±5.6 kg/m2, FBS level of 134.2±25.3mg/dL, 2-hPPBS level of 234.0±64.3mg/dL, HbA1c level of 8.5±2.1%, cholesterol level of 207.3±38.8mg/dL, and triglyceride level of 155.4±17.1mg/dL. There were significant differences among breast cancer women with stage-I disease, stage-II disease, and stage-III disease regarding BMI, FBS, 2-hPPBS, HbA1c, cholesterol, and triglyceride levels, with p values of 0.001, 0.001, 0.001, 0.001, 0.001, and 0.01, respectively (table 3).

Table 4 revealed that breast cancer women with ductal carcinoma in situ had BMI of 22.9±1.4 kg/m2, FBS level of 85.2±7.9mg/dL, 2-hPPBS level of 128.7±5.7mg/dL, HbA1c level of 4.8±0.5%, cholesterol level of 165.7±5.4mg/dL, and triglyceride level of 139.3±5.9mg/dL. Breast cancer women with invasive duct carcinoma had BMI of 32.0±6.1 kg/m2, FBS level of 130.3±30.4mg/dL, 2-hPPBS level of 221.6±72.5mg/dL, HbA1c level of 7.8±2.2%, cholesterol level of 202.2±39.9mg/dL, and triglyceride level of 154.9±16.1mg/dL. Significant differences were observed between breast cancer women with ductal carcinoma in situ and breast cancer women with invasive duct carcinoma regarding BMI, FBS, 2-hPPBS, HbA1c, cholesterol, and triglyceride levels, with p values of 0.001, 0.001, 0.001, 0.001, 0.001, and 0.01, respectively (table 4). Furthermore, significant positive correlations were observed between clinical stages of breast cancer and serum levels of FBS (figure 1), 2-hPPBS (figure 2), and HbA1c (figure 3).

**Discussion**

Evidence regarding the association between diabetes and breast cancer stages has been mixed; some studies have shown more advanced breast cancer stage among diabetes patients [15], but other failed to find an association [16]. In present study, type-2 diabetic women with breast cancer had significantly higher BMI, cholesterol, and triglyceride levels compared to non-diabetic breast cancer women. Similarly, a positive association between diabetes and risk of breast cancer has been reported in females [17]. Obesity and diabetes are considered some of the risk factors for the onset of breast cancer; obesity is considered as one of the predisposing factors for cancer even in non-diabetic individuals with impaired fasting glucose levels [1]. Obesity, insulin resistance and chronic inflammation are the characteristic features in metabolic syndrome [18]. Insulin resistance could lead to compensatory hyperinsulinemia, which enhanced the cross-binding of insulin to insulin-like growth factor-1 (IGF-1) receptors expressed on breast epithelial cells; the activated IGF-1 pathway may stimulate the carcinogenesis and progression of cancer [19]. A possible suggested pathway for the association between type-2 DM and breast cancer characteristics is hyperinsulinemia that might stimulate tumor growth [6].

In current study, on comparing type-2 diabetic to non-diabetic breast cancer women, there were non-significant differences regarding percentage of HER2 receptor positivity (11.8% vs. 9.8%) as well as percentage of PR-positivity (64.7% vs. 56.9%), but the percentage of ER-positivity was significantly higher in type-2 diabetic breast cancer women compared to non-diabetic breast cancer women (84.3% vs. 51%). Consistently, differences between cancer subtypes, e.g., 80% versus 60% ER-positive tumors, were reported in women with and without diabetes [3]. Moreover, some studies determined the association between diabetes and hormone receptor status (HER2, ER, and PR) [6]. One study reported a significant association between diabetes and ER receptor [20]. Three studies [5], [15], [20] found that breast cancer among women with diabetes was more often PR-negative; none of these studies reported a significant association between diabetes and HER2 receptor.

The present study showed significant differences regarding pathologic subtypes of breast cancer between type-2 diabetic and non-diabetic breast cancer women, where invasive ductal carcinoma was significantly higher in type-2 diabetic compared to non-diabetic breast cancer women. Concurrently, indolent tumors may progress more rapidly in patients with diabetes, or diabetes may lead to higher metastatic potential [21]. This association in women with longer-duration diabetes further supports a mitogenic effect of diabetes on breast tumors, which would be the most salient in women who were exposed to diabetes for a longer latency period prior to breast cancer diagnosis [22]. In addition, women with type-2 diabetes mellitus were at risk of being diagnosed with a larger tumor, a more advanced lymph nodes status, a more advanced tumor stage, and a higher grade tumor than women without diabetes [6].

In current study, majority of the type-2 diabetic breast cancer women presented with stage-III disease and none presented with stage-I disease, whereas, the majority of non-diabetic breast cancer women presented with stage-I disease and minority presented with stage-III disease. Consistently, women with diabetes are significantly more likely to present with advanced-stage breast cancer compared to those without diabetes [9]. Other studies demonstrated more advanced stage of breast cancer among women with diabetes [15], [23]. In addition, women with T2DM are at increased risk to be diagnosed with a more aggressive type of breast cancer than women without [6]. The risk of advanced-stage breast cancer was greatest in younger women and those with longer-standing diabetes; these findings suggest that diabetes may predispose women to more rapidly progressive breast cancer, leading to more advanced-stage disease at diagnosis [9].

In present study, progressive advancing of clinical stages of breast cancer was positively correlated with progressive elevation of diabetes parameters (FBS, 2-hPPBS, HbA1c). Breast cancer women presented with stage-III disease had significantly higher BMI, FBS, 2-hPPBS, and HbA1c levels compared to women presented with stage-I disease. In addition, breast cancer women presented with invasive ductal carcinoma had significantly higher BMI, FBS, 2-hPPBS, and HbA1c levels compared to women presented with ductal carcinoma in situ. Consistently, breast cancer patients with diabetes were significantly more likely to present with advanced-stage cancer compared to women without diabetes, which may contribute to the higher mortality faced by breast cancer patients with diabetes [9].

**Conclusion and recommendation**:

In conclusion, type-2 DM is considered a risk factor for development of breast cancer; in addition, in type-2 diabetic women, breast cancer is often diagnosed at advanced stages and characterized by being of more aggressive pathologic subtype. Whether type-1 DM has similar effect on breast cancer was not evaluated in this study. Further studies are recommended to evaluate whether proper control of diabetic status to an optimum targets could affect the progression of breast cancer and its response to therapy.

**Acknowledgment**:

The authors would like to acknowledge the histopathologists, clinical pathologists, technicians, and other medical staffs for their support in achievement of this study.

**References**

1. Abudawood M (2019): Diabetes and cancer: A comprehensive review. J Res Med Sci.; 24:94-106.
2. Lam E, Batty G, Huxley R, Martiniuk A, Barzi F, and Lam T (2011): Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region. Ann Oncol.; 22; 730-738.
3. Heleen K, Vibeke J, Pernille V, Marie L, Sten C, Joyce S, et al (2017): Diabetes and breast cancer subtypes. PloS One; 12(1):e0170084.
4. Torre L, Bray F, Siegel R, Ferlay J, Lortet J, and Jemal A (2015): Global cancer statistics, 2012. CA Cancer J Clin,; 65: 87-108.
5. Liao S, Li J, Wang L, Zhang Y, Wang c, and Hu M (2010): Type-2 diabetes mellitus and characteristics of breast cancer in China. Asian Pac J Cancer Prev.; 11:933-937.
6. Jetty A, Myrthe P, Pauline A, Amber A, Heleen K, Ron M, et al (2019): Type-2 Diabetes, but not insulin (Analog) treatment, is associated with more advanced stages of breast cancer: A national linkage of cancer and pharmacy registries. Diabetic care, 2019; Diabetic Care Published Ahead on Print, published online January 24; page 1-9.
7. Gallagher E and LeRoith D (2010): The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab.; 21: 610-618.
8. Grimberg A (2003): Mechanisms by which IGF-1 may promote cancer. Cancer Boil Ther.; 2: 630-635.
9. Lorraine L, Hadas D, Peter C, Longdi R, Ophira G, Paula A, et al (2015): The association between diabetes and breast cancer stage at diagnosis: a population-based study. Breast Cancer Res treat.; 150: 613-620.
10. Rose D and Vona-Davis L (2012): Cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr Relat Cancer; 19: R225-241.
11. Goldhirsch A, Wood W, Coates A, Gelber R, Thurlimann B, and Senn H (2011): Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann Oncol.; 22:1736-1747.
12. American Diabetic Association (ADA) (2014): Diagnosis and classification of diabetes. Diabetes Care; Jan; 37 (supplement 1); S81-S90.
13. Veronesi U, Zurrida S, Viala G, Galimberti V, Arnone P, and Nole F: Rethinking TNM (2009): a breast Cancer classification to Guide to Treatnent and Facilitate research, Breast Journal; May-June; volume 15; Issue 3, pages 291-295.
14. Peacock J, Peacock L, and Peacock P (2011): Oxford handbook of medical statistics. Oxford University Press. Print Publication Dat Nov.; Print ISBV-139780199551286.
15. Hou G, Zhang S, Zhang X, Wang P, Hao X, and Zhang J (2013): Clinical pathological characteristics and prognostic analysis of 1013 breast cancer patients with diabetes. Breast Cancer Res. Treat.; 137(30): 807-816.
16. Yancik R (2001): Effect of age and comorbidity in post-menopausal breast cancer patients aged 55 years and older. JAMA; 285(7): 885-892.
17. Key T, Verkasalo P, and Banks E (2001): epidemiology of breast cancer. Lancet Oncol.; 2:133-140.
18. Mendonca F, de Sousa F, Barbosa A, Martins S, Araujo R, Soares R, et al (2015): Metabolic syndrome and risk of cancer: which link?. Metabolism; 64(2):182-189.
19. Jung S, Ho G, Rohan T, Strickler H, Bea J, Papp J, et al (2017): Interaction on insulin-like growth factor-1 and insulin resistance-related genetic variants with lifestyle factors on postmenopausal breast cancer risk. Breast Cancer Res Treat.; 164(2):475-495.
20. Wolf I, Sadetzki S, and Gluck I (2006): Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer; 42:1077-1082.
21. Godsland IF (2010): Insulin resistance and hyperinsulinemia in the development and progression of cancer. Clin. Sci.; 118(5): 315-332.
22. Lawlor D, Smith G, Ebrahim S (2004): Hyperinsulinemia and increased risk of breast cancer: findings from the British women's Heart and Health study. Cancer Causes Control.; 15(3): 267-275.
23. Fleming ST (2005): Comorbidity as a predictor stage of illness for patients with breast cancer. Med. Care; 43(2): 132-140.

Table 1: various parameters according to diabetic status of breast cancer women

Total number = 102 women

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **Non-diabetic breast cancer women**  **n = 51**  **(mean±SD)** | **Type-2 diabetic breast cancer women**  **n = 51**  **(mean±SD)** | **P value** |
| Age (in years)  (mean ±SD) | 45.5±11.1 | 47.2±9.2 | 0.39 |
| BMI (kg/m2)  (mean ±SD) | 23.4±1.5 | 34.7±4.5 | 0.01 |
| Cholesterol (mg/dL)  (mean ±SD) | 166.6±5.5 | 214.2±39.8 | 0.001 |
| Triglyceride (mg/dL)  (mean ±SD) | 140.1±6.1 | 159.5±15.8 | 0.01 |
| FBS mg/dL  (mean ±SD) | 85.9±8.4 | 145.4±18.1 | 0.001 |
| 2-hPPBS mg/dL  (mean ±SD) | 128.6±5.8 | 254.5±54.1 | 0.001 |
| HbA1c (%)  (mean ±SD) | 4.7±0.5 | 9.1±1.4 | 0.001 |

Table 2: frequency and percentage of women according to some parameters

Total number = 102 women

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Parameter** | | **Non-diabetic breast cancer**  **n = 51** | **Type-2 diabetic breast cancer**  **n = 51** | **P value** |
| HER2 receptor | Negative (n; %) | 46 (90.2%) | 45 (88.2%) | 0.974 |
| Positive (n; %) | 5 (9.8%) | 6 (11.8%) |
| ER receptor | Negative (n; %) | 25 (49%) | 8 (15.7%) | 0.001 |
| Positive (n; %) | 26 (51%) | 43 (84.3%) |
| PR receptor | Negative (n; %) | 22 (43.1%) | 18 (35.3%) | 0.417 |
| Positive (n; %) | 29 (56.9%) | 33 (64.7%) |
| Pathologic subtypes | Ductal carcinoma in situ (n;%) | 33 (64.7%) | 2 (3.9%) | 0.001 |
| Invasive ductal carcinoma (n;%) | 18 (35.3%) | 49 (96.1%) |
| Stages | Stage-I (n; %) | 30 (58.8%) | 0 (0.0%) | 0.001 |
| Stage-II (n; %) | 16 (31.4%) | 21 (41.2%) |
| Stage-III (n; %) | 5 (9.8%) | 30 (58.8%) |

Table 3: various parameters according to breast cancer stages

Number = 102 women

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Parameter** | **Stage-I**  **n = 30**  **(mean±SD)** | **Stage-II**  **n = 37**  **(mean±SD)** | **Stage-III**  **n = 35**  **(mean±SD)** | **P value** |
| BMI (kg/m2) | 22.8±1.4 | 28.2±4.3 | 35.3±5.6 | 0.001 |
| FBS (mg/dL) | 84.8±7.4 | 123.1±35.0 | 134.2±25.3 | 0.001 |
| 2-hPPBS (mg/dL) | 128.3±5.7 | 202.7±68.6 | 234.0±64.3 | 0.001 |
| HbA1c % | 4.8±0.5% | 6.9±2.2% | 8.5±2.1% | 0.001 |
| Cholesterol (mg/dL) | 165.9±5.4 | 194.2±40.2 | 207.3±38.8 | 0.001 |
| Triglyceride (mg/dL) | 140.0±6.2 | 152.5±15.6 | 155.4±17.1 | 0.01 |

Table 4: various parameters according to pathologic subtypes of breast cancer

Number = 102 women

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **Ductal carcinoma in situ**  **n = 33**  **(mean±SD)** | **Invasive duct carcinoma**  **n = 69**  **(mean±SD)** | **P value** |
| BMI (kg/m2) | 22.9±1.4 | 32.0±6.1 | 0.001 |
| FBS (mg/dL) | 85.2±7.9 | 130.3±30.4 | 0.001 |
| 2-hPPBS (mg/dL) | 128.7±5.7 | 221.6±72.5 | 0.001 |
| HbA1c % | 4.8±0.5% | 7.8±2.2% | 0.001 |
| Cholesterol (mg/dL) | 165.7±5.4 | 202.2±39.9 | 0.001 |
| Triglyceride (mg/dL) | 139.3±5.9 | 154.9±16.1 | 0.01 |

Figure 1: correlation between FBS and breast cancer stages




Figure 2: correlation between 2-hPPBS and breast cancer stages



Figure 3: correlation between HbA1c and breast cancer stages

